Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610756 | 0.85 | FOLH1 (0.44) | TBXA2RFOLH1SLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL27868600 | 0.82 | SIGMAR1 (0.52) | TBXA2RFOLH1SLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL27868602 | 0.82 | SIGMAR1 (0.52) | TBXA2RFOLH1SLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL67079 | 0.80 | TBXA2R (0.58) | TBXA2RFOLH1CYP2D6LMNARAB9A | |
| SCHEMBL523236 | 0.79 | HTT (0.42) | TBXA2RFOLH1SLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL14610742 | 0.79 | HTT (0.42) | TBXA2RFOLH1SLC6A9ALDH1A1CYP2D6 | |
| SCHEMBL2743522 | 0.78 | TBXA2R (0.50) | TBXA2RFOLH1LMNA | |
| SCHEMBL6512170 | 0.78 | TBXA2R (0.50) | TBXA2RFOLH1LMNA | |
| SCHEMBL27868603 | 0.78 | TBXA2R (0.50) | TBXA2RFOLH1LMNA | |
| SCHEMBL10024995 | 0.76 | FKBP1A (0.50) | ALDH1A1CYP2C9CYP2C19LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | CES1, CMA1, CYP51A1 | TBXA2R 3083/4885FOLH1 814/4885SLC6A9 4674/4885 |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | TPSD1, PCSK9, PEPD | TBXA2R 2703/4885FOLH1 1115/4885SLC6A9 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.